Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Mauro
Michael J
MJ
Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR, USA. maurom@ohsu.edu
D001549:Benzamides; D020732:Cytogenetic Analysis; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D018365:Neoplasm, Residual / Q000175:diagnosis; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl